糖タンパク質41(gp41)治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Glycoprotein 41 (gp41) - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0502
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:70
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Glycoprotein 41 (gp41) – Pipeline Review, H2 2019
Summary

According to the recently published report ‘Glycoprotein 41 (gp41) – Pipeline Review, H2 2019′; Glycoprotein 41 (gp41) pipeline Target constitutes close to 20 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Glycoprotein 41 (gp41) – Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41 fusion peptides with the target cell causes a formation of an intermediate structure which bridges and fuses the viral and host membranes together.

The report ‘Glycoprotein 41 (gp41) – Pipeline Review, H2 2019′ outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 1, 6 and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 1 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS).

Scope

- The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)
- The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glycoprotein 41 (gp41) – Overview
Glycoprotein 41 (gp41) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glycoprotein 41 (gp41) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glycoprotein 41 (gp41) – Companies Involved in Therapeutics Development
Frontier Biotechnologies Inc
Longevity Biotech Inc
Minka Therapeutics SA
Molecular Express Inc
Mymetics Corp
Navigen Inc
Novodux
Osel Inc
Protheragen Inc
Sanofi Pasteur SA
Glycoprotein 41 (gp41) – Drug Profiles
albuvirtide LAR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPT-31 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-007 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV-1 vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human immunodeficiency virus (virus like particles) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBT-5001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Target GP120 and GP41 for HIV – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit GP41 for HIV Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target GP41 for HIV Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPER-656 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MYMV-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MYMV-201 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides to Inhibit gp41 for HIV-1 Infection – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit Glycoprotein 41 and Glycoprotein 120 for Infectious Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target GP120 and Gp41 for HIV-1 Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhbit GP41 for HIV Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAC-02 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAC-3S – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCP-2438 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glycoprotein 41 (gp41) – Dormant Products
Glycoprotein 41 (gp41) – Discontinued Products
Glycoprotein 41 (gp41) – Product Development Milestones
Featured News & Press Releases
Dec 10, 2019: Navigen announces FDA clearance of its IND application to initiate first-in-human studies for CPT31, a novel, D-peptide HIV entry inhibitor
Apr 29, 2019: Mymetics receives funding from NIH for Novel HIV Vaccine Study
Aug 21, 2018: Frontier Biotech’s novel long-acting, all-injectable anti-HIV two-drug combo IND allowed by the US FDA
Jun 07, 2018: Frontier Biotech receives marketing authorization from China FDA for Aikening (albuvirtide for injection), China’s first new drug for the treatment of HIV
Sep 18, 2017: Navigen Awarded $4.9MM to Advance its HIV Entry Inhibitor CPT31
Sep 13, 2017: Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines
Jul 26, 2017: Navigen Presents Promising Pre-Clinical Data on CPT31 at the 9th International AIDS Society Conference on HIV Science
Nov 28, 2016: First new HIV vaccine efficacy study in seven years has begun
Oct 20, 2016: Dr. Michael Kay Presents Recent Data on Navigen’s HIV Entry Inhibitor, CPT31, at the 2016 HIVR4P meeting
Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development
Aug 24, 2016: Navigen Awarded $500,000 Grant to Support Depot Formulation of its HIV Drug Candidate
Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial
May 20, 2016: InnaVirVax Obtained FDA Authorization for a Phase 2 Clinical Trial with VAC-3S in HIV Functional Cure in the US
May 18, 2016: Large-scale HIV vaccine trial to launch in South Africa
Apr 11, 2016: Mymetics’ HIV vaccine candidate confirms promise in preclinical study with Texas Biomed
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Frontier Biotechnologies Inc, H2 2019
Pipeline by Longevity Biotech Inc, H2 2019
Pipeline by Minka Therapeutics SA, H2 2019
Pipeline by Molecular Express Inc, H2 2019
Pipeline by Mymetics Corp, H2 2019
Pipeline by Navigen Inc, H2 2019
Pipeline by Novodux, H2 2019
Pipeline by Osel Inc, H2 2019
Pipeline by Protheragen Inc, H2 2019
Pipeline by Sanofi Pasteur SA, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

【掲載企業】

Frontier Biotechnologies Inc
Longevity Biotech Inc
Minka Therapeutics SA
Molecular Express Inc
Mymetics Corp
Navigen Inc
Novodux
Osel Inc
Protheragen Inc
Sanofi Pasteur SA

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[糖タンパク質41(gp41)治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆